drugset
drugset / Trial / NCT00003491

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003491 ↗

Phase 2 Terminated 17 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for Stage IV lung cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV lung cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV lung cancer.

Timeline

Start
1996-03-20
Primary completion
1998-07-31
Completion
1998-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown — Intravenous
Subject antineoplaston A10 Small molecule — Intravenous

Indications

No indication recorded.